Join to View Full Profile
2800 L StSuite 300Sacramento, CA 95816
Phone+1 916-453-3300
Dr. Behl is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2006 - 2009- Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 2003 - 2006
Christian Medical College LudhianaClass of 1996
Certifications & Licensure
MN State Medical License 2025 - 2026
CA State Medical License 2009 - 2025
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC) Start of enrollment: 2019 Jul 26
- Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer Start of enrollment: 2020 Aug 13
- Ashwagandha for Cognitive Dysfunction Start of enrollment: 2023 Jan 01
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- 1 citations[F]F-AraG Uptake in Vertebral Bone Marrow May Predict Survival in Patients with Non-Small Cell Lung Cancer Treated with Anti-PD-(L)1 Immunotherapy.Jelena Levi, Millie Das, Minal S Vasanawala, Deepti Behl, Martin Pomper
Journal of Nuclear Medicine. 2024-12-03 - Palbociclib in Patients With Head and Neck Cancer and Other Tumors WithAlterations: Results From the Targeted Agent and Profiling Utilization Registry Study.Francis P Worden, Evan Pisick, Michael Rothe, Pam K Mangat, Elizabeth Garrett-Mayer
JCO Precision Oncology. 2024-10-01 - Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer WithAlterations: Results From the Targeted Agent and Profiling Utilization Registry Study.Timothy L Cannon, Michael Rothe, Pam K Mangat, Elizabeth Garrett-Mayer, Vi K Chiu
Journal of Clinical Oncology. 2024-09-20
Press Mentions
The Cancer Treatment Within YouNovember 20th, 2019
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
